Dube; Marie-Pierre

Patent Applications and Registrations

Patent applications and USPTO patent grants for Dube; Marie-Pierre.The latest application filed is for "methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events".

Company Profile

5.8.15

Dube; Marie-Pierre - Montreal CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent Grant 11,401,554 - Dube , et al. August 2, 2	2022-08-02
Methods For Treating Or Preventing Cardiovascular Disorders And Lowering Risk Of Cardiovascular Events App 20210290623 - DUBE; Marie-Pierre ; et al.	2021-09-23
Methods For Delaying Occurrence Of New-onset Type 2 Diabetes And For Slowing Progression Of And Treating Type 2 Diabetes App 20210236442 - DUBE; Marie-Pierre ; et al.	2021-08-05
Cetp Inhibitors For Therapeutic Use App 20210017597 - Dube; Marie-PIerre ; et al.	2021-01-21
Genetic Markers For Predicting Responsiveness To Therapy With Hdl-raising Or Hdl Mimicking Agent App 20200239960 - Dube; Marie-Pierre ; et al.	2020-07-30
Methods For Treating Or Preventing Cardiovascular Disorders And Lowering Risk Of Cardiovascular Events App 20200222406 - DUBE; Marie-Pierre ; et al.	2020-07-16
CETP inhibitors for therapeutic use Grant 10,711,303 - Dube , et al.	2020-07-14
Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent Grant 10,584,385 - Dube , et al.	2020-03-10
Cetp Inhibitors For Therapeutic Use App 20190226020 - Dube; Marie-Pierre ; et al.	2019-07-25
Methods For Treating Or Preventing Cardiovascular Disorders And Lowering Risk Of Cardiovascular Events App 20190070178 - DUBE; Marie-Pierre ; et al.	2019-03-07
Cetp Inhibitors For Therapeutic Use App 20180155784 - Dube; Marie-Pierre ; et al.	2018-06-07
Dalcetrapib for therapeutic use Grant 9,909,178 - Dube , et al. March 6, 2	2018-03-06
Genetic Markers For Predicting Responsiveness To Therapy With Hdl-raising Or Hdl Mimicking Agent App 20170233812 - Dube; Marie-Pierre ; et al.	2017-08-17
Genetic Markers For Predicting Responsiveness To Therapy App 20160244826 - Dube; Marie-Pierre ; et al.	2016-08-25
Genotyping Tests And Methods For Evaluating Plasma Creatine Kinase Levels App 20160230231 - Dube; Marie-Pierre ; et al.	2016-08-11
Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy Grant 8,563,241 - Dube , et al. October 22, 2	2013-10-22
Mutations in human UBIAD1 Grant 8,334,369 - Samuels , et al. December 18, 2	2012-12-18
Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy App 20100304393 - Dube; Marie-Pierre ; et al.	2010-12-02
Mutations In Human Ubiad1 App 20100190161 - Samuels; Mark Elliot ; et al.	2010-07-29
System and method for electronically managing medical data files in order to facilitate genetic research Grant 7,734,656 - Bessette , et al. June 8, 2	2010-06-08
Hsan II related gene and expression products and uses thereof App 20060166207 - Lafreniere; Ronald G. ; et al.	2006-07-27
System and method for electronically managing medical data files in order to facilitate genetic research App 20050060195 - Bessette, Luc ; et al.	2005-03-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.